Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Lupin Ltd Regulatory Filings 2021

Feb 10, 2021

61031_rns_2021-02-10_f3848a71-5be1-413a-8878-2b3f928d128c.pdf

Regulatory Filings

Open in viewer

Opens in your device viewer

February 10, 2021

ISE Limited Department of Corporate Services, P. J. Towers, Dalai Street, Mumbai Samachar Marg, MUMBAI -400001.

National Stock Exchange of India Limited Exchange Plaza, Bandra Kuria Complex, Bandra (East), MUMBAI - 400 051.

Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

Enclosed is a Press Release as regards launch of a new ayurvedic energy supplement for men, Be One, by LupinLife, consumer healthcare division of the Company.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

FOR LUPIN LIMITED

R. V. SATAM COMPANY SECRETARY (ACS -11973)

End- : a/a.

LUPIN LIMITED

Registered Office: 3'dFloor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai -400055 India. Tel : (91-22) 6640 2323. Corporate Identity Number: L24100MH1983PLCO29442 www.lupin.com

REUTERS: LUPIN.B0 BLOOMBERG: LPCIN
BSE.500257 NSE: LUPIN

life Launches Be One, Ayurvedic Energy Supplement

Be One is a natural, non-addictive and steroid-free daily health supplement for men

Mumbai, India, February 10, 2021: LupinLife, consumer healthcare business of global pharma major, Lupin Limited, today announced the launch of a new ayurvedic energy supplement for men, Be One.

Be One is a 100% Ayurvedic health and wellness supplement specially developed for men to help them stay energized and healthy. It is scientifically tested and contains 100% ayurvedic natural ingredients including ashwagandha, shatavari and shilajit that boost energy levels and improve immunity. Ministry of Ayush has recognised ashwagandha and pippali for their immunomodulatory properties. Additionally, both are also recognized as ingredients for building immunity by National Clinical Management Protocol for COVID-19.

Commenting on the launch, Rajeev Sibal, President, India Region Formulations, Lupin said, "With LupinLife, we are committed towards improving health and quality of life of people. We are delighted to launch Be One, an ayurvedic energy and immunity supplement, specially developed for men to take care of their daily energy and immunity needs. The supplement contains natural ingredients and powerful adaptogens to boost energy levels and restore vitality."

"We believe good health is the foundation for happiness and therefore, we are excited to launch Be One for men as a health and wellness enabler," said Anil V Kaushal, Head of LupinLife Consumer Healthcare. "Consumers are recognizing the need for increased personal vitality, energy and revitalization. We are proud to share the common purpose of helping people lead healthier lives and therefore, with the launch of Be One, which is a natural, non-addictive and steroid-free daily health supplement for men, we aim to improve their overall well-being."

About Lupin Limited

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (Cl), central nervous system (CNS) and women's health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions. For the nine months ended December 31, 2020, the Company invested 9.8% of its revenues on research and development.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

BSE: 500257 NSE: LUPIN REUTERS: LUPIN.B0 BLOOMBERG: LPCIN

Please visit www.lupin.com for more information.

Follow us on Twitter: https://twittercom/LupinGlobal I LinkedIn: https://www.linkedin.com/company/lupin Facebook: http://www.facebook.com/LupinWorld/

For further information or queries please contact —

Shweta Munjal Arvind Bothra Manjira Sharma
Head —Corporate Communications Head - Investor Relations / Corporate M&A General Manager —Corporate Communications
Email: [email protected] Email: [email protected] Email: [email protected]